- Regulatory Status
- RUO
- Other Names
- Bone Morphogenetic Protein Receptor Type 1A (BMPR1A), Activin Receptor-Like Kinase 3 (ALK3) , BMP Type-1A Receptor , Serine/Threonine-Protein Kinase Receptor R5 (SKR5 ), CD292 Antigen, CD292
- Ave. Rating
- Submit a Review
- Product Citations
- publications
Cat # | Size | Price | Quantity Check Availability | Save | ||
---|---|---|---|---|---|---|
794104 | 25 µg | £121 | ||||
794106 | 100 µg | £221 |
Select size of product is eligible for a 40% discount! Promotion valid until December 31, 2024. Exclusions apply. To view full promotion terms and conditions or to contact your local BioLegend representative to receive a quote, visit our webpage.
The transforming growth factor (TGF) superfamily controls a large number of biological responses and plays a prominent role during embryonic development, regulation of cell growth, differentiation, and apoptosis. Forty distinct TGF members have been identified in vertebrates and they are generally divided into two branches, the TGF/activin/nodals and the bone morphogenetic proteins (BMPs). The BMP family regulates embryogenesis and postnatal tissue homeostasis. BMP proteins signal through serine/threonine kinase receptors known as type I and type II receptors. Four type I receptors: BMPR1A (ALK3), BMPR1B (ALK6), ACVRL1 (ALK1), and ACVR1 (ALK2), and three type II receptors: BMPR2 (BMPRII), ACVR2A (ACTRIIA) and ACVR2B (ACTRIIB) mediate BMP signaling. After activation, the type I receptors activate receptor SMADS (SMAD1, 5, 8) through phosphorylation. BMPR1A signaling restricts preosteoblast proliferation and stimulates osteoblast activity in mouse. Disruption of BMPR1A in an osteoblast-specific manner leads to an increase of trabecular bone mass in the femora, spine, and ribs. Systemic administration of a soluble BMPR1A fusion protein (mBMPR1A-mFc) in vivo increases bone mass and bone strength, due to an early increase in osteoblast number and bone formation rate, and suppression of DKK1 expression. Human BMPR1A-Fc binds BMP-2/4 specifically with high affinity and prevents downstream signaling.
Product DetailsProduct Details
- Source
- Human BMPR1A, amino acid (Gln24-Arg152) (Accession: # P36894.2), with a linker (GS) and a C-terminal human IgG (Pro100-Lys330), was expressed in 293E cells.
- Molecular Mass
- The 362 amino acid recombinant protein has a predicted molecular mass of approximately 40.27 kD. The DTT-reduced and non-reduced protein migrates at approximately 55 kD and 100 kD by SDS-PAGE, respectively. The predicted Nterminal amino acid is Gln.
- Purity
- > 95%, as determined by Coomassie stained SDS-PAGE
- Formulation
- 0.22 µm filtered protein solution is in pH 7.2, PBS.
- Endotoxin Level
- Less than 0.1 EU per µg cytokine as determined by the LAL method
- Concentration
- 10 and 25 µg sizes are bottled at 200 µg/mL. 100 µg size and larger sizes are lot-specific and bottled at the concentration indicated on the vial. To obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.
- Storage & Handling
- Unopened vial can be stored between 2°C and 8°C for up to 2 weeks at -20°C for up to six months, or at -70°C or colder until the expiration date. For maximum results, quick spin vial prior to opening. The protein can be aliquoted and stored at -20°C or colder. Stock solutions can also be prepared at 50 - 100 µg/mL in appropriate sterile buffer, carrier protein such as 0.2 - 1% BSA or HSA can be added when preparing the stock solution. Aliquots can be stored between 2°C and 8°C for up to one week and stored at -20°C or colder for up to 3 months. Avoid repeated freeze/thaw cycles.
- Activity
- Human BMPR1A-Fc chimera inhibits the alkaline phosphatase production induced by recombinant human BMP-4 (15 ng/mL, Cat. No. 595202) in ATDC5 mouse chondrogenic cells in a dose-dependent manner. The ED50 for this effect is 0.1 - 0.5 μg/mL.
- Application
-
Bioassay
- Application Notes
-
BioLegend carrier-free recombinant proteins provided in liquid format are shipped on blue-ice. Our comparison testing data indicates that when handled and stored as recommended, the liquid format has equal or better stability and shelf-life compared to commercially available lyophilized proteins after reconstitution. Our liquid proteins are validated in-house to maintain activity after shipping on blue ice and are backed by our 100% satisfaction guarantee. If you have any concerns, contact us at tech@biolegend.com.
Antigen Details
- Structure
- Disulfide-linked homodimer
- Distribution
-
Ubiquitously expressed in most types of cells, osteoblasts, granulosa cells of growing follicles.
- Function
- Regulates postnatal osteoblast function and bone remodeling, fertility, suppression of ovarian tumor development; mediates different biological responses in the developing nervous system and formation of a glial scar following spinal cord injury.
- Ligand/Receptor
- BMP-2, BMP-4
- Bioactivity
- Human BMPR1A inhibits the alkaline phosphatase production induced by recombinant human BMP-4 in ATDC5 mouse chondrogenic cells in a dose-dependent manner.
- Cell Type
- Embryonic Stem Cells, Mesenchymal Stem Cells, Neural Stem Cells, Osteoblasts
- Biology Area
- Cell Biology, Cell Proliferation and Viability, Immuno-Oncology, Stem Cells
- Molecular Family
- Fc Receptors, Soluble Receptors
- Antigen References
-
- Mishina Y, et al. 2004. J Biol Chem. 279:27560.
- Izzi L and Attisano L. 2004. Oncogene. 23:2071.
- Okamoto M, et al. 2006. J Bone Miner Res. 21:1022.
- Edson MA, et al. 2010. Mol Endocrinol. 24:1251.
- Sahni V, et al. 2010. J Neurosci. 30:1839.
- Baud'huin M, et al. 2012. Proc Natl Acad Sci USA. 109:12207.
- Lim J, et al. 2016. Development. 143:339
- Gene ID
- 657 View all products for this Gene ID
- UniProt
- View information about BMPR1A on UniProt.org
Related FAQs
- Why choose BioLegend recombinant proteins?
-
• Each lot of product is quality-tested for bioactivity as indicated on the data sheet.
• Greater than 95% Purity or higher, tested on every lot of product.
• 100% Satisfaction Guarantee for quality performance, stability, and consistency.
• Ready-to-use liquid format saves time and reduces challenges associated with reconstitution.
• Bulk and customization available. Contact us.
• Learn more about our Recombinant Proteins. - How does the activity of your recombinant proteins compare to competitors?
-
We quality control each and every lot of recombinant protein. Not only do we check its bioactivity, but we also compare it against other commercially available recombinant proteins. We make sure each recombinant protein’s activity is at least as good as or better than the competition’s. In order to provide you with the best possible product, we ensure that our testing process is rigorous and thorough. If you’re curious and eager to make the switch to BioLegend recombinants, contact your sales representative today!
- What is the specific activity or ED50 of my recombinant protein?
-
The specific activity range of the protein is indicated on the product datasheets. Because the exact activity values on a per unit basis can largely fluctuate depending on a number of factors, including the nature of the assay, cell density, age of cells/passage number, culture media used, and end user technique, the specific activity is best defined as a range and we guarantee the specific activity of all our lots will be within the range indicated on the datasheet. Please note this only applies to recombinants labeled for use in bioassays. ELISA standard recombinant proteins are not recommended for bioassay usage as they are not tested for these applications.
- Have your recombinants been tested for stability?
-
Our testing shows that the recombinant proteins are able to withstand room temperature for a week without losing activity. In addition the recombinant proteins were also found to withstand four cycles of freeze and thaw without losing activity.
- Does specific activity of a recombinant protein vary between lots?
-
Specific activity will vary for each lot and for the type of experiment that is done to validate it, but all passed lots will have activity within the established ED50 range for the product and we guarantee that our products will have lot-to-lot consistency. Please conduct an experiment-specific validation to find the optimal ED50 for your system.
- How do you convert activity as an ED50 in ng/ml to a specific activity in Units/mg?
-
Use formula Specific activity (Units/mg) = 10^6/ ED50 (ng/mL)
Follow Us